Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Blueport Acquisition LtdBPAC · Entity 6967 | Director · CEO and Chairman · 10% owner | November 13, 2025 | December 08, 2025 |
| Q BioMed Inc.QBIO] · Entity 126730 | Director · Chief Legal Officer · 10% owner | May 26, 2022 | May 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Blueport Acquisition Ltd
Report date November 13, 2025 · Filed December 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary Share, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 1,634,750 |
Reported balance
After 2025-11-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-11-13 · Purchase · Acquired 197,250 · Balance 1,634,750 F1: Reflects the 197,250 private units owned by Blueport Acquisition Corporation, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share, and one right to receive one-sixth (1/6th) of one Class A ordinary share upon the consummation of the Issuer's initial business combination. The private units were purchased at $10.00 per unit for an aggregate purchase price of $ 1,972,500. The sponsor is managed by its two principals, William Rosenstadt and Roy Jiang, and is legally and beneficially owned (i) 50% by William Rosenstadt and (ii) 50% by Roy Jiang. By virtue of their shared control of our sponsor, William Rosenstadt and Roy Jiang may be deemed to have beneficial ownership of the shares held directly by our sponsor. The address for the sponsor is 366 Madison Avenue, 3rd Floor New York, NY 10017. Mr. Rosenstadt disclaims any beneficial ownership of the shares held by the sponsor, except to the extent of his pecuniary interest therein. |
| Right to receive one-sixth of one Class A Ordinary ShareSEC Table II · derivative / convertible security | IndirectSee Footnote | 197,250 |
Reported balance
After 2025-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-13 · Purchase · Acquired 197,250 · Balance 197,250 F2: The rights convert automatically into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination. If the business combination has not been consummated within the applicable time period specified in the Issuer's Amended and Restated Memorandum and Articles of Association, the rights shall expire and shall be worthless. F1: Reflects the 197,250 private units owned by Blueport Acquisition Corporation, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share, and one right to receive one-sixth (1/6th) of one Class A ordinary share upon the consummation of the Issuer's initial business combination. The private units were purchased at $10.00 per unit for an aggregate purchase price of $ 1,972,500. The sponsor is managed by its two principals, William Rosenstadt and Roy Jiang, and is legally and beneficially owned (i) 50% by William Rosenstadt and (ii) 50% by Roy Jiang. By virtue of their shared control of our sponsor, William Rosenstadt and Roy Jiang may be deemed to have beneficial ownership of the shares held directly by our sponsor. The address for the sponsor is 366 Madison Avenue, 3rd Floor New York, NY 10017. Mr. Rosenstadt disclaims any beneficial ownership of the shares held by the sponsor, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the 197,250 private units owned by Blueport Acquisition Corporation, the Issuer's sponsor (the "sponsor"). Each private unit consists of one Class A ordinary share, and one right to receive one-sixth (1/6th) of one Class A ordinary share upon the consummation of the Issuer's initial business combination. The private units were purchased at $10.00 per unit for an aggregate purchase price of $ 1,972,500. The sponsor is managed by its two principals, William Rosenstadt and Roy Jiang, and is legally and beneficially owned (i) 50% by William Rosenstadt and (ii) 50% by Roy Jiang. By virtue of their shared control of our sponsor, William Rosenstadt and Roy Jiang may be deemed to have beneficial ownership of the shares held directly by our sponsor. The address for the sponsor is 366 Madison Avenue, 3rd Floor New York, NY 10017. Mr. Rosenstadt disclaims any beneficial ownership of the shares held by the sponsor, except to the extent of his pecuniary interest therein.
F2: The rights convert automatically into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination. If the business combination has not been consummated within the applicable time period specified in the Issuer's Amended and Restated Memorandum and Articles of Association, the rights shall expire and shall be worthless.
Q BioMed Inc.
Report date May 26, 2022 · Filed May 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 926,910 |
Reported balance
After 2022-05-26 transaction · row 1
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 250,000 · Balance 926,910 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 900 | $3.73 | $3,357.00 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 7 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,849 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| February 22, 2017 Filed Mar 30, 2017 15:36 UTC Amendment | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 5,000 | $3.37 | $16,850.00 |
DisclosureSEC source: 0001461959-17-000003 · primary_doc.xml · nonDerivative · entry 6 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,749 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017 for the sale of up to 92,000 shares of common stock. Such sales were outside of the holder's investment decision. Read SEC document |
| February 22, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 5,000 | $3.37 | $16,850.00 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 6 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,749 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| February 17, 2017 Filed Mar 30, 2017 15:36 UTC Amendment | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 1,800 | $3.86 | $6,948.00 |
DisclosureSEC source: 0001461959-17-000003 · primary_doc.xml · nonDerivative · entry 5 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,749 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017 for the sale of up to 92,000 shares of common stock. Such sales were outside of the holder's investment decision. Read SEC document |
| February 17, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 1,800 | $3.86 | $6,948.00 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 5 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,749 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| February 16, 2017 Filed Mar 30, 2017 15:36 UTC Amendment | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001461959-17-000003 · primary_doc.xml · nonDerivative · entry 4 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,549 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017 for the sale of up to 92,000 shares of common stock. Such sales were outside of the holder's investment decision. Read SEC document |
| February 16, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 4 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,549 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| February 14, 2017 Filed Mar 30, 2017 15:36 UTC Amendment | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 4,651 | $3.27 | $15,208.77 |
DisclosureSEC source: 0001461959-17-000003 · primary_doc.xml · nonDerivative · entry 3 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,549 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017 for the sale of up to 92,000 shares of common stock. Such sales were outside of the holder's investment decision. Read SEC document |
| February 14, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 4,651 | $3.27 | $15,208.77 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 3 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,549 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| February 10, 2017 Filed Mar 30, 2017 15:36 UTC Amendment | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 5,000 | $4.38 | $21,900.00 |
DisclosureSEC source: 0001461959-17-000003 · primary_doc.xml · nonDerivative · entry 2 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017 for the sale of up to 92,000 shares of common stock. Such sales were outside of the holder's investment decision. Read SEC document |
| February 10, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 5,000 | $4.38 | $21,900.00 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 2 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| February 09, 2017 Filed Mar 30, 2017 15:36 UTC Amendment | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 3,800 | $4.40 | $16,720.00 |
DisclosureSEC source: 0001461959-17-000003 · primary_doc.xml · nonDerivative · entry 1 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017 for the sale of up to 92,000 shares of common stock. Such sales were outside of the holder's investment decision. Read SEC document |
| February 09, 2017 Filed Mar 30, 2017 10:31 UTC | Q BioMed Inc. QBIO · Entity 126730 | SaleCommon Stock | 3,800 | $4.40 | $16,720.00 |
DisclosureSEC source: 0001461959-17-000002 · primary_doc.xml · nonDerivative · entry 1 Rosenstadt William S · CIK 0001461959 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on January 17, 2017. Read SEC document |
| July 18, 2016 Filed Dec 14, 2016 13:23 UTC | Q BioMed Inc. QBIO · Entity 126730 | GiftCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001461959-16-000003 · primary_doc.xml · nonDerivative · entry 1 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,000 F1 · price: The disposal of securities was a bona fide gift. Read SEC document |
| July 15, 2016 Filed Dec 14, 2016 13:23 UTC | Q BioMed Inc. QBIO · Entity 126730 | GrantWarrant · Derivative | 37,500 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001461959-16-000003 · primary_doc.xml · derivative · entry 6 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,075,000 Underlying: Common Stock · 37,500 shares Expires 2021-07-15 F3 · price: Issued for director services. Read SEC document |
| July 15, 2016 Filed Dec 14, 2016 13:23 UTC | Q BioMed Inc. QBIO · Entity 126730 | GrantWarrant · Derivative | 37,500 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001461959-16-000003 · primary_doc.xml · derivative · entry 5 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,500 Underlying: Common Stock · 37,500 shares Expires 2021-07-15 F3 · price: Issued for director services. Read SEC document |
| July 15, 2016 Filed Dec 14, 2016 13:23 UTC | Q BioMed Inc. QBIO · Entity 126730 | GrantWarrant · Derivative | 37,500 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001461959-16-000003 · primary_doc.xml · derivative · entry 4 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 37,500 shares Expires 2021-07-15 F3 · price: Issued for director services. Read SEC document |
| July 15, 2016 Filed Dec 14, 2016 13:23 UTC | Q BioMed Inc. QBIO · Entity 126730 | GrantWarrant · Derivative | 37,500 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001461959-16-000003 · primary_doc.xml · derivative · entry 3 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,500 Underlying: Common Stock · 37,500 shares Expires 2021-07-15 F3 · price: Issued for director services. Read SEC document |
| July 15, 2016 Filed Dec 14, 2016 13:23 UTC | Q BioMed Inc. QBIO · Entity 126730 | PurchaseWarrant · Derivative | 50,000 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001461959-16-000003 · primary_doc.xml · derivative · entry 2 Rosenstadt William S · CIK 0001461959 · Director · General Counsel · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By self as partner of Ortoli Rosenstadt LLP. Disclosed balance after: 925,000 Underlying: Common Stock · 50,000 shares Expires 2021-07-15 F2 · price: Issued for legal services. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.